Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics

Rhea-AI Summary

Primordial Genetics announced an exclusive license agreement with Arcturus Therapeutics Holdings Inc. (ARCT) for a novel RNA polymerase enzyme, aimed at enhancing the manufacturing of long, high-quality RNAs for therapeutic use. This collaboration is expected to significantly improve the efficiency and cost-effectiveness of mRNA production, which is vital for drug and vaccine development. Primordial's technology emphasizes innovative RNA manufacturing processes that could lead to advancements in pharmaceuticals, ultimately aiming to address pressing health needs.

Positive

• Exclusive license granted to ARCT for a novel RNA polymerase, improving RNA manufacturing.
• Potential for higher efficiency and lower cost in mRNA production, essential for therapeutics.

Negative

• None.

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic production systems for nucleic acids, today announced granting Arcturus Therapeutics Holdings Inc. ("Arcturus", Nasdaq: ARCT), a clinical-stage messenger RNA (mRNA) medicines company, an exclusive license of an enzyme for an RNA polymerase (RNApol). The enzyme was discovered by Primordial to meet the challenge of manufacturing high-quality, long RNAs for therapeutic applications.

mRNA based medicines represent a promising new approach to drug and vaccine development. Primordial owns proprietary technology relating to RNA manufacturing, specifically its collection of RNA polymerase genes, promoters, and proteins that may be used to synthesize RNA. Primordial is focused on developing improved RNApols for higher efficiency and lower cost manufacturing of mRNAs used in therapeutics and vaccines.

"We look forward to the meaningful achievements Arcturus can make with this licensed Primordial Genetics RNA polymerase, from clinical trials to a marketable RNA product that can be used in pharmaceuticals to improve or save lives," said Helge Zieler, PhD, founder and President of Primordial Genetics. "We are thrilled for this Primordial and Arcturus collaboration that meets the core of our mission to connect innovation with social needs via new, biologically-based alternatives to traditional therapeutics.

About Primordial Genetics

Primordial Genetics is a synthetic biology company founded in 2013 and based in San Diego, California. The company is the world leader in constructive biology; a revolutionary new way of practicing biotechnology that creates novel genes from genomic building blocks to accelerate the evolution of highly efficient enzymes and microbes. Primordial's product focus is to develop efficient production processes for DNA and RNA manufacturing to enable biologically-based alternatives to traditional therapeutics, nutritional products, agriculture and fuels. For more information, visit: www.primordialgenetics.com

View original content:http://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html

SOURCE Primordial Genetics

FAQ

What is the recent license agreement involving Arcturus Therapeutics (ARCT)?

Arcturus Therapeutics has secured an exclusive license from Primordial Genetics for a novel RNA polymerase enzyme, aimed at enhancing RNA manufacturing.

How does the RNA polymerase benefit Arcturus Therapeutics (ARCT)?

The RNA polymerase is expected to improve the efficiency and cost-effectiveness of mRNA production for therapeutic applications.

What does Primordial Genetics specialize in related to Arcturus Therapeutics (ARCT)?

Primordial Genetics specializes in synthetic biology, focusing on developing advanced RNA manufacturing technologies.

When was the license agreement between Primordial Genetics and Arcturus Therapeutics (ARCT) announced?

The agreement was announced on June 2, 2021.